FDA approves generic combo HIV- 1 drug

  • May 24, 2012

The FDA has approved a generic version of the combination lamivudine and zidovudine tablets for the treatment of HIV-1 infection, according to an FDA press release.

The 150 mg and 300 mg tablets will be manufactured by Aurbindo Pharma Limited of Hyderabad, India and is indicated for use in combination with other antiretroviral therapies for the treatment of HIV-1.

“The FDA has determined that the generic is bioequivalent and therapeutically equivalent to the reference drug (Combivir, GlaxoSmithKline). The approval means that the generic formulation may be marketed in the United States,” according to the release.

Comments

Healio is intended for health care provider use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will Healio be used for medical advice to patients.

[X]